Gubra

Executive Summary

Gubra is a privately held Danish biotechnology company with a dual business model: it provides preclinical contract research services (CRO) while also developing its own proprietary drug pipeline. Founded in 2008 and headquartered in Hørsholm, the company focuses on metabolic diseases such as obesity, diabetes, and their complications. Its CRO division offers specialized capabilities in in vivo pharmacology, molecular histology, and peptide chemistry, serving pharmaceutical and biotech partners. This service business generates recurring revenue and provides operational stability, funding part of the company's internal research. Gubra’s proprietary pipeline targets novel mechanisms in metabolic disease, leveraging its deep expertise in peptide-based drug discovery and preclinical validation. The company has completed two discrete financing rounds to support its operations and pipeline advancement. While specific financial details are not disclosed, Gubra continues to invest in its research programs and expand its service offerings. The company's dual strategy reduces risk by combining early-stage cash flows from services with high-upside proprietary assets. Near-term value drivers include progress in its own therapeutic candidates, potential new partnerships, and further funding to advance lead programs into clinical development. Gubra remains a lean, science-driven organization with a focused approach to metabolic diseases, positioning it as a potential acquisition target or licensing partner for larger pharmaceutical companies seeking innovative obesity and diabetes therapies.

Upcoming Catalysts (preview)

• H2 2026Next financing round to support pipeline advancement70% success
• TBDPartnership or licensing deal for proprietary metabolic candidate40% success
• Q4 2026Preclinical proof-of-concept data for lead obesity program60% success